Want to see HK:8329 full AI Analyst Report?
8329 Stock Chart & Stats
HK$0.16
>-HK$0.01(-0.63%)
At close: 4:00 PM EST
HK$0.16
>-HK$0.01(-0.63%)
Day’s Range― - ―
52-Week RangeHK$0.09 - HK$0.18
Previous CloseN/A
Volume90.00K
Average Volume (3M)330.65K
Market Cap
HK$179.55M
Enterprise ValueHK$177.90
Total Cash (Recent Filing)HK$209.45M
Total Debt (Recent Filing)HK$73.02M
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Aug 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield5.02%
Share Statistics
EPS (TTM)-0.02
Shares Outstanding426,000,000
10 Day Avg. Volume371,000
30 Day Avg. Volume330,653
Financial Highlights & Ratios
PEG Ratio0.02
Price to Book (P/B)0.37
Price to Sales (P/S)0.25
P/FCF Ratio1.92
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Low LeverageThe company's very low debt-to-equity provides durable financial flexibility, reducing refinancing and interest-rate risk. This conservatism supports continued R&D, working capital and dividend capacity during earnings stress, and gives management optionality for strategic investments.
Strong 2025 Free Cash FlowRobust free cash flow in 2025 demonstrates strong cash conversion and working-capital management even amid a net loss. Sustainable cash generation underpins operations, funds capex or dividends, and provides a buffer against earnings volatility, improving long-term survivability.
Positive Operating EarningsGenerating positive operating earnings while net results were negative indicates core operations remain viable. That operational profitability suggests issues may be non-recurring or financial in nature, making it more plausible management can restore net margins without structural business redesign.
Bears Say
Net Loss And Margin CompressionA shift from modest profits to a net loss with materially compressed gross margin signals weakened pricing power or higher costs. Thinner margins reduce the firm's capacity to absorb cost shocks and erode cover for dividends and reinvestment, increasing structural risk to long-term profitability.
Revenue DeclineSustained revenue decline reduces scale benefits and may reflect softer demand or lost market share. Continued top-line contraction limits margin recovery potential, constrains cash flow upside, and makes it harder to leverage fixed costs, threatening durable earnings recovery without renewed growth drivers.
Weakened Equity BaseA declining equity base and negative return on equity indicate earnings have eroded capital, reducing financial headroom. This deterioration limits strategic flexibility, increases vulnerability to future losses, and raises the bar for management to rebuild returns through profitable growth or capital actions.
8329 FAQ
What was Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price range in the past 12 months?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H lowest stock price was HK$0.09 and its highest was HK$0.18 in the past 12 months.
What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s market cap is HK$179.55M.
When is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s upcoming earnings report date is Aug 07, 2026 which is today.
How were Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s earnings last quarter?
Currently, no data Available
Is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H overvalued?
According to Wall Street analysts Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price is currently Overvalued.
Does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pay dividends?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H pays a Notavailable dividend of HK$0.164 which represents an annual dividend yield of 5.02%. See more information on Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H dividends here
What is Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H have?
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H has 426,000,000 shares outstanding.
What happened to Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H?
Currently, no hedge funds are holding shares in HK:8329
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
84.21%
12-Months-Change
Fundamentals
Return on Equity
5.02%
Trailing 12-Months
Asset Growth
-20.91%
Trailing 12-Months
Company Description
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H
Based in Shenzhen, People's Republic of China, Shenzhen Neptunus Interlong Bio-technique Company Limited and its subsidiaries are primarily engaged in the research, development, production, and sale of pharmaceuticals. The company also handles the procurement, distribution, and marketing of medicines and health food items, while undertaking research and development in biological technology. Its manufacturing operations encompass herbal medicines, generic drugs, and medical devices. This entity operates as a subsidiary of Shenzhen Neptunus Bio-engineering Company Limited.
Shenzhen Neptunus Interlong Bio-Technique Co. Ltd. Class H (8329) Earnings & Revenues
Technical Analysis
HUTCHMED (China)
―
Essex Bio-Technology
―
Jilin Province Huinan Changlong Bio Pharmacy Co. Ltd. Class H
―
CanSino Biologics, Inc. Class H
―
Ab&B Bio-Tech CO., LTD. JS Class H
―